INOpulse receives Intention to Grant European Patent notice

Bellerophon Therapeutics Inc. announced last week that it has received a Notice of Intention from the European Patent Office that will grant it a European Patent that will protect its INOpulse program.

The patent, called “System of Administering a Pharmaceutical Gas to a Patient,” will distinguish INOpulse from its competitors. The INOpulse delivery system has the ability to deliver the right amount of pharmaceutical gas despite the patient’s inspiration rate or volume. Upon approval, the patent will be accepted in 38 European countries.

Patents for this type of system exists in only six countries in the world, the United States, Australia, China, Hong Kong, Japan and Mexico. Applications to bring this type of technology to Brazil and Canada are currently pending. The INOpulse system also has patents in the U.S. for the tri-lumen cannula and the indexed valve that connects to the drug cartridge. Patents are pending in other countries for these devices as well, including the European Union.

Bellerophon’s main emphasis for the INOpulse system is to move forward with the nitric oxide therapy for patients dealing with pulmonary hypertension (PH). It is in Phase 2 of testing in PH and looks to have results this year.